Indirubin modulates CD4+ T-cell homeostasis via PD1/PTEN/AKT signalling pathway in immune thrombocytopenia

Yajing Zhao1 | Panpan Han1 | Lei Liu2 | Xiaojie Wang3 | Pengcheng Xu1 |
Haoyi Wang1 | Tianshu Yu1 | Yunqi Sun1 | Lizhen Li1 | Tao Sun1 | Xinguang Liu1 |
Hai Zhou1 | Jihua Qiu4 | Liang Wang1 | Jun Peng1,5,6 | Shuqian Xu1 |
Ming Hou1,5,6,7

1Department of Haematology, Qilu Hospital, Shandong University, Jinan, Shandong, China
2Department of Urology, Qilu Hospital, Shandong University, Jinan, Shandong, China
3Department of Dermatology, Qilu Hospital, Shandong University, Jinan, Shandong, China
4Department of Geriatric Medicine, Qilu Hospital, Shandong University, Jinan, Shandong, China
5Shandong Provincial Key Laboratory of Immunohaematology, Qilu Hospital, Shandong University, Jinan, Shandong, China
6Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Shandong University, Jinan, Shandong, China
7Leading Research Group of Scientific Innovation, Department of Science and Technology of Shandong Province, Qilu Hospital, Shandong University, Jinan, Shandong, China

Abstract

Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by an immune mediated decrease in platelet number. Disturbance of CD4+ T-cell homeostasis with simultaneous decrease of CD4+CD25+Foxp3+ regulatory T cells (Tregs) as well as unrestricted proliferation and activation of peripheral CD4+ effector T cells underpin the pathophysiology of ITP. Indirubin is an active ingredient of a traditional Chinese herb called Indigofera tinctoria L. which is clinically used for the treatment of ITP patients. Whether indirubin targets the Tregs/effectector T cell-axis to restore platelet number is unknown. In our in vitro studies, indirubin could significantly enhance the number and function of Tregs and meanwhile dampen the activation of effectector T cells in a dose-dependent manner. In our murine model of ITP, indirubin observed to restore the expression of programmed cell-death 1 (PD1) and phosphatase and tensin homolog (PTEN) on the CD4+ T cells of ITP patients, leading to the subsequent attenuation of the AKT/mTOR pathway. Furthermore, these observations were recapitulated in an active murine model of ITP with a prominent platelet response. Thus, our results identified a potentially novel mechanism of the therapeutic action of indirubin in the treatment of ITP through regulating the homeostasis of CD4+ T cells in a PD1/PTEN/AKT signalling pathway.
The importance of T-cell homeostasis in attenuating autoimmunity is further evidenced in the current clinical treatment of ITP. Both clinical and experimental studies show treatments such as intravenous immunoglobulin, dexamethasone, rituximab, and thrombopoietic mimetics, exert their therapeutic effects at least partially through modulating Tregs activation and expansion, and/or dampening the survival and proliferation of effector T cells.14,17,22-24

Indirubin is an active ingredient of a traditional Chinese herb called *Indigofera tinctoria* L. and is most well-known for its clinical use in the treatment of chronic myelogenous leukemia.25 There are also reports of indirubin possessing anti-viral, anti-bacterial and anti-inflammatory properties.26-30 In murine models of ITP and ulcerative colitis, indirubin was effective therapeutically through down-regulating the immune response and increasing the percentage of Tregs.27,31 Clinically, *I tinctoria* L. is used as a traditional Chinese medical therapy for thrombocytopenia patients. However, the efficacy of *I tinctoria* L. in the treatment of ITP still needs to be confirmed by appropriate clinical trials and the endogenous mechanisms of action remains to be explored.

Programmed cell-death 1 (PD1) is a co-receptor that is inducibly expressed on T cells. Tregs activation and expansion in parallel with PD1 signalling are critical for the maintenance of CD4+ T-cell homeostasis and elimination of either can result in its breakdown.32 Dysregulation of the PD1 pathway can be an important contributor to autoimmune pathogenesis, as has been shown in rheumatoid arthritis (RA), systemic lupus erythematosus, and multiple sclerosis (MS).33-38 Furthermore, PD1 and its ligand PDL1 were reported to be decreased in the PBMCs of ITP patients, which suggested the important role of the PD1 pathway in the pathogenesis of ITP.39

Here we demonstrate that the therapeutic effects of indirubin may be achieved through the regulation of CD4+ T-cell homeostasis in ITP by promoting the development and function of Tregs as well as reducing the activation of effector T cells via a PD1/phosphatase and tensin homolog (PTEN)/AKT signalling pathway.

2 MATERIALS AND METHODS

2.1 Patients and controls

A total of 36 consenting patients with ITP (19 females and 17 males; 15-77 years old; median age, 47) were enrolled between March 2016 and May 2018 in the Department of Haematology, Qilu Hospital, Shandong University, China. All ITP patients fulfilled the clinical diagnosis criteria recommended by the 2011 American Society of Haematology guidelines.40 The patient's platelet counts ranged between 1 × 10^9/L and 95 × 10^9/L, with a median count of 15 × 10^9/L. The demographic and key clinical information of ITP patients are summarized in Table 1 and Table 2. Previous therapy were completed at least 3 weeks prior to enrollment. In parallel, 28 consenting healthy volunteers (13 females and 15 males; age range, 23-71 years; median age, 40 years) were recruited to establish healthy controls. And their platelet counts ranged between 143 × 10^9/L and 358 × 10^9/L, with a median count of 256 × 10^9/L (Table 2). All study subjects donated 4 or 5 mL of heparinized venous peripheral blood. Our study was approved by the Institutional Review Boards of Qilu Hospital, Shandong University, China. All blood samples were collected after obtaining the informed consent from each participant before being included in the study.

2.2 Mice and animal model

Wild-type (WT) C57BL/6 mice were obtained from the Centre for New Drug Evaluation of Shandong University and served as platelet donors. Severe combined immunodeficient (SCID) mice with a C57BL/6 background (J001913, 6-8 weeks of age, male) were purchased from Jackson Lab (Bar Harbor, Maine, USA) and served as spleen-cell transfer recipients. C57BL/6 CD61-KO mice (B6.129S2-
Itgb3tm1Hyn/JSemJ; Stock No: 008819) were generously provided by Dr. Junling Liu from Shanghai Jiaotong University, School of Basic Medicine. For the establishment of ITP murine models, blood was drawn by retro-orbital bleeding, and centrifuged at 60 g for 10 minutes to collect the platelet rich plasma (PRP). Platelets were gathered from PRP via centrifugation at 800 g for 5 minutes, and adjusted to a concentration of $10^9$/mL for immunization. C57BL/6 CD61 KO mice were transfused weekly with 100 µL of $10^8$ platelets from WT mice for three consecutive weeks. The immunized CD61 KO mice were euthanized, and their spleens were harvested and single-cell suspension prepared. On the day of splenocytes transfer, SCID mice were subjected to 180 cGy total body irradiation to inhibit recipient

| Patient no. | Sex/age (y) | Platelet count ($10^9$/L) | Course of disease (mo) | Anti-GP1lb/IIIa | Anti-GP1lb/IIb | Major previous drugs | Bleeding symptoms |
|-------------|-------------|---------------------------|-----------------------|----------------|----------------|----------------------|------------------|
| 1           | F/61        | 20                        | 5                     | –              | –              | DEX                  | PT, EC, GH        |
| 2           | M/60        | 2                         | 2                     | –              | –              | TPO                  | PT               |
| 3           | M/45        | 33                        | 3                     | –              | –              | None                 | None             |
| 4           | F/26        | 17                        | 3                     | –              | –              | None                 | None             |
| 5           | F/36        | 2                         | 5                     | +              | –              | DEX                  | EC               |
| 6           | M/51        | 95                        | 0                     | –              | –              | DEX                  | EC, GH           |
| 7           | F/48        | 17                        | 0                     | +              | +              | DEX                  | PT               |
| 8           | F/46        | 13                        | 2                     | –              | +              | Pred                 | GUH              |
| 9           | M/21        | 8                         | 12                    | +              | –              | DEX, TPO, Rit        | None             |
| 10          | M/39        | 26                        | 84                    | –              | –              | DEX, TPO             | EC, GH           |
| 11          | M/60        | 8                         | 72                    | –              | –              | TPO, Rit, IVIg        | PT, GH           |
| 12          | M/28        | 39                        | 4                     | –              | –              | DEX                  | EC, GH, EP       |
| 13          | F/61        | 65                        | 260                   | –              | +              | DEX                  | EC, GH, EP       |
| 14          | F/25        | 16                        | 1.5                   | –              | –              | DEX                  | GH               |
| 15          | M/75        | 9                         | 1                     | +              | +              | None                 | GH               |
| 16          | M/61        | 15                        | 3                     | +              | –              | None                 | None             |
| 17          | M/52        | 31                        | 6                     | –              | –              | None                 | None             |
| 18          | F/46        | 56                        | 3                     | –              | –              | None                 | None             |
| 19          | M/58        | 16                        | 260                   | –              | –              | DEX, SP, TPO         | PT, EC, GH       |
| 20          | F/53        | 6                         | 36                    | +              | –              | Pred                 | None             |
| 21          | F/71        | 2                         | 3                     | –              | +              | DEX                  | None             |
| 22          | M/37        | 55                        | 48                    | –              | –              | None                 | None             |
| 23          | F/32        | 1                         | 4                     | +              | –              | None                 | PT, EP           |
| 24          | F/47        | 32                        | 12                    | +              | +              | None                 | None             |
| 25          | F/15        | 10                        | 36                    | –              | –              | Pred, IVIg            | PT, GH           |
| 26          | M/64        | 16                        | 2                     | +              | –              | DEX                  | EC, GH           |
| 27          | M/58        | 3                         | 120                   | –              | –              | TPO, IVIg             | PT, EC           |
| 28          | M/62        | 8                         | 30                    | –              | –              | DEX, Rit, TPO        | PT, GH           |
| 29          | F/19        | 8                         | 12                    | –              | +              | DEX, TPO, Rit        | PT, GH, EP       |
| 30          | F/46        | 12                        | 6                     | –              | –              | Pred, Olse            | PT               |
| 31          | F/27        | 2                         | 108                   | –              | +              | DEX                  | EC               |
| 32          | M/77        | 28                        | 48                    | +              | –              | Pred, TPO             | EP               |
| 33          | F/52        | 23                        | 1                     | –              | –              | Dex                  | EP               |
| 34          | F/41        | 19                        | 24                    | –              | –              | Dex                  | EC, GUH          |
| 35          | F/57        | 7                         | 1                     | –              | +              | DEX, TPO             | EC, PT           |
| 36          | M/24        | 12                        | 0                     | –              | –              | TPO                  | NONE             |

TABLE 1 Clinical characteristics of ITP patients

EC, ecchymoses; EP, epistaxis; GH, gingival hemorrhage; GUH, genitourinary hemorrhage; ITP, immune thrombocytopenia; IVIg, intravenous gamma globulin; Olse, oseltamivir; Pred, prednisone; PT, petechiae; Rit, rituximab; SP, splenectomy; TPO, thrombopoietin.

*The month number (n) in the course of disease was regarded as the disease course less than n + 1 mo.
Significance between the two groups was determined by paired Student’s t test. Among the PBMCs after cultured with different doses of indirubin were not changed apparently in the ITP and healthy control groups.

For ITP patients, the percentages of Tregs among CD4+ T cells were significantly increased after indirubin treatment at the dose of 0.2 and 1 µmol/L (8.37 ± 1.1 vs 8.89 ± 1.15, n = 7, P = 0.0335; 8.37 ± 1.1 vs 9.15 ± 1.25, n = 7, P = 0.0224). In the culturing of PBMCs from healthy controls, the percentages of Tregs among CD4+ T cells were significantly increased after 2 µmol/L indirubin treatment (8.63 ± 1.26 vs 9.55 ± 1.87, n = 7, P = 0.0488). Dexamethasone was used as a positive control for the induction of Tregs (8.37 ± 1.1 vs 10.92 ± 1.82, n = 7, P = 0.0302 for indirubin treated groups; 8.63 ± 1.26 vs 11.93 ± 2.59, n = 7, P = 0.0333 for healthy control group). The percentage of CD4+ T cells among the PBMCs after cultured with different doses of indirubin were not changed apparently in the ITP and healthy control groups.

Significance between the two groups was determined by paired Student’s t test. The division index of effector T cells proliferation. Tregs significantly suppressed the proliferation of effector T cells both in the dimethyl sulfoxide (DMSO) and indirubin-treated groups (DMSO Teff 0.52 ± 0.31 vs DMSO Teff+Tregs 0.31 ± 0.33, P = 0.0039; indirubin Teff 0.49 ± 0.41 vs indirubin Teff+Tregs 0.27 ± 0.32, P = 0.0039).

Indirubin significantly enhanced the inhibitory function of Tregs compared with DMSO (P = 0.0117).

Representative histograms of CFSE dilution of CD4+CFSE+ effector T cells. Differences between two groups were determined by Wilcoxon matched-pairs signed rank test, n = 9, *P < 0.05, **P < 0.01.

TABLE 2 Baseline characteristics of ITP patients and healthy controls

|                      | ITP patients | Healthy controls | P values |
|----------------------|--------------|------------------|----------|
| Median Age, y (range)| 47 (15-77)   | 40 (23-71)       | 0.622    |
| Gender, n (%)        | 17 (47.2%)   | 15 (53.5%)       | 0.614    |
| Median platelet count, x10^9/L (range) | 15 (1-95)   | 256 (143-358)   | <0.0001  |

ITP, immune thrombocytopenia.

rejection and enhance engraftment. Within 3 hours of irradiation, mice were injected intraperitoneally with 100 µL of the immunized splenocytes preparations (5 x 10^6 splenocytes/mouse). (2’Z)-indirubin (indirubin, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in corn oil (Sigma-Aldrich) at 5 mg/mL and stored at 4°C. Immune thrombocytopenia murine models were randomly separated into two groups. The indirubin group mice received an intraperitoneal injection of indirubin (40 mg/kg) and the control group received the same volume of corn oil (Sigma-Aldrich) at 5 mg/mL and stored at 4°C. Immune thrombocytopenia murine models were randomly separated into two groups.

Peripheral blood mononuclear cells (PBMCs) from the patients and healthy controls were isolated from heparinized venous peripheral blood using Ficoll–Hypaque centrifugation (Amersham Biosciences, Piscataway, NJ, USA). Isolation of circulating CD4+ T cells was performed using anti-CD4-coated magnetic beads and MS column (Miltenyi Biotec, Bergisch Gladbach, Germany) separation. The purity of the isolated cells was found to be >90% by flow cytometry.

2.3 | Isolation and culturing of PBMCs and CD4+ T cells

Peripheral blood mononuclear cells (PBMCs) from the patients and healthy controls were isolated from heparinized venous peripheral blood using Ficoll–Hypaque centrifugation (Amersham Biosciences, Piscataway, NJ, USA). Isolation of circulating CD4+ T cells was performed using anti-CD4-coated magnetic beads and MS column (Miltenyi Biotec, Bergisch Gladbach, Germany) separation. The purity of the isolated cells was found to be >90% by flow cytometry.

PBMCs or CD4+ T cells were resuspended in RPMI-1640 medium (Life Technologies, Paisley, UK) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Grand Island, NY, USA), 1% penicillin and streptomycin (Solarbio, Beijing, China), and recombinant human IL-2 (5 ng/mL, R&D Systems, Minneapolis, MN, USA), anti-human CD3 antibodies (1 ng/mL; eBioscience, San Diego, CA, USA), and anti-human CD28 antibodies (1 ng/mL; eBioscience). The cells were then seeded on 24-well plates.

Indirubin was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) to generate a stock solution of 5 mg/mL. Cultures of PBMCs or CD4+ T cells were treated with indirubin at a concentration of 0.01, 0.1, 0.2, 1, 2, and 10 µM, whereas 1% DMSO was used as vehicle controls. After 72 hours of incubation with indirubin or DMSO, PBMCs or CD4+ T cells were collected for flow cytometry, RNA extraction, and western blotting.

2.4 | Flow cytometry

Tregs were detected using a regulatory T-cell staining kit (eBioscience). Briefly, a total of 1 x 10^6 cultured human PBMCs were harvested from 24-well plates following respective treatments. For the preparation of mouse single-cell suspensions, the spleens, thymuses and bone marrow from ITP mice were smashed and lysed using ACK lysis buffer to remove red blood cells. Cells were then washed two times by centrifugation at 300 g for 10 minutes and adjusted to a concentration of 1 x 10^6 cells/mL for flow cytometry analysis. Subsequently, the single-cell suspensions were stained as per manufacturer’s instructions using anti-human or anti-mouse CD4, CD25, and Foxp3 conjugated-antibodies (eBioscience).

The expression of PD1, PTEN and PDL1 was determined using anti-human or anti-mouse PD1 and PDL1 conjugated-antibodies (eBioscience), and anti-human/mouse PTEN (Miltenyi Biotec). Mouse antigen presenting cells (APCs) were identified with anti-mouse CD80 and anti-mouse CD86 conjugated-antibodies (BD Biosciences, SanJose, CA, USA).

The activation of CD4+ T cells was measured by immunofluorescence staining using anti-human CD4, CD25, CD45RA and CD45RO conjugated-antibodies (eBioscience). For apoptosis analysis, PBMCs cultured with the respective doses of indirubin or 1% DMSO were

Indirubin increased the number and suppressive function of Tregs. (A) The gating strategy and representative dot plots for identification of CD4+CD25+Foxp3+ Tregs. (B) In the culturing of peripheral blood mononuclear cells (PBMCs) from immune thrombocytopenia (ITP) patients, the percentages of Tregs among CD4+ T cells were significantly increased after indirubin treatment at the dose of 0.2 and 1 µmol/L (8.37 ± 1.1 vs 8.89 ± 1.15, n = 7, P = 0.0335; 8.37 ± 1.1 vs 9.15 ± 1.25, n = 7, P = 0.0224). In the culturing of PBMCs from healthy controls, the percentages of Tregs among CD4+ T cells were significantly increased after 2 µmol/L indirubin treatment (8.63 ± 1.26 vs 9.55 ± 1.87, n = 7, P = 0.0488). Dexamethasone was used as a positive control for the induction of Tregs (8.37 ± 1.1 vs 10.92 ± 1.82, n = 7, P = 0.0302 for ITP group; 8.63 ± 1.26 vs 11.93 ± 2.59, n = 7, P = 0.0333 for healthy control group). (C,D) The percentage of CD4+ T cells among the PBMCs after cultured with different doses of indirubin were not changed apparently in the ITP and healthy control groups.

Significance between the two groups was determined by paired Student’s t test. (F) The division index of effector T cells proliferation. Tregs significantly suppressed the proliferation of effector T cells both in the dimethyl sulfoxide (DMSO) and indirubin-treated groups (DMSO Teff 0.52 ± 0.31 vs DMSO Teff+Tregs 0.31 ± 0.33, P = 0.0039; indirubin Teff 0.49 ± 0.41 vs indirubin Teff+Tregs 0.27 ± 0.32, P = 0.0039).

Indirubin significantly enhanced the inhibitory function of Tregs compared with DMSO (P = 0.0117). (G) Representative histograms of CFSE dilution of CD4+CFSE+ effector T cells. Differences between two groups were determined by Wilcoxon matched-pairs signed rank test, n = 9, *P < 0.05, **P < 0.01.
2.5 | Suppression assay

Fresh CD4⁺CD25⁻ T cells and CD4⁺CD25⁺ Tregs were isolated from PBMCs using a CD4⁺CD25⁺ Regulatory T Cell Isolation Kit (Miltenyi Biotec) per manufacturer instructions. CD4⁺CD25⁻ T cells (effector T cells) were labelled with CFSE (5 µmol/L; Sigma-Aldrich), seeded at 2 × 10⁵ cells/well, and then co-cultured with or without Tregs at a ratio of 4:1 on a 96 well-plate. The wells were also supplemented with IL-2 (5 ng/mL; BD), anti-human CD3 antibodies (1 ng/mL; eBioscience), and anti-human CD28 antibodies (1 ng/mL; eBioscience). Sample data was acquired for flow cytometry analysis 6 days after cells incubation with 1 µmol/L indirubin or 1% DMSO. The data was analyzed using Flow Jo software.

2.6 | Western blotting

Isolated CD4⁺ T cells cultured with 1 µmol/L indirubin or 1% DMSO were lysed in radio-immunoprecipitation assay (RIPA) buffer (Bestbio). Immunoblots were performed using polyclonal rabbit anti-human GAPDH (ZSGB-BIO, Beijing, China), polyclonal rabbit anti-human mammalian target of rapamycin (mTOR), p-mTOR, AKT, p-AKT, PTEN, and p-PTEN antibodies (Cell Signaling Technology, NJ, USA). Semi-quantitative evaluation of a particular protein’s total level was analyzed by calculating the band of interest with respect to the housekeeping GAPDH signal. The level of phosphorylated proteins was measured using the ratio of phosphorylated protein to total protein. Results were expressed as fold increase relative to control (DMSO treated CD4⁺ T cells).

2.7 | Quantitative real-time PCR

Trizol reagent (Takara, Japan) was used to isolate total RNA from cultured CD4⁺ T cells. RNA was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Perfect Real Time; Takara) according to the manufacturer’s instructions. Multiplex real-time RT-PCR was performed for PTEN (forward: 5’-GCTGTGGTTGCCACAAAGTGCC-3’; reverse: 5’-GCAGGTAGAAGGCAACTCTGCCA-3’), PD1 (forward: 5’-CTCAGGGTGACAGAGAGAAG-3’; reverse: 5’-GACACACCCAC-CAGGGTTT-3’) and the endogenous control GAPDH (forward: 5’-GCACGTCAAGGGCTGAAG-3’; reverse: 5’-TGTTGAGACGC-CAGTGGA-3’) on a LightCycler® 480 System (Roche Applied Science, Mannheim, Germany). In order to calculate relative changes in gene expression, target genes were compared to the housekeeping gene GAPDH using the comparative delta Ct (ΔΔCt) method.

2.8 | Statistical analysis

Data were reported as mean values ±SD or Median with interquartile range, and were assessed for statistical significance using SPSS. Differences between pre- and post- treatment groups were determined by paired Student’s t test and differences between two independent groups were compared using the Student’s t test, and the data were expressed as mean values ±SD. For the data not normally distributed, the Wilcoxon matched-pairs test and Mann-Whitney test were used, and the data were expressed as Median with interquartile range. The P values <0.05 were considered to be of significance.

3 | RESULTS

3.1 | Indirubin increased the number and suppressive function of Tregs among ITP patients

Tregs were reported to be quantitatively and functionally impaired in ITP patients, which was thought to contribute to disregulation of...
immune homeostasis. It has been reported that indirubin could increase the number of Tregs as well as ameliorate thrombocytopenia in ITP murine models. Using PBMCs isolated from ITP patients and healthy controls, we tested whether indirubin could exert an influence on Tregs. In our study, indirubin could increase the number of Tregs in the culture of PBMCs from ITP patients at the dose of 0.2 and 1 µmol/L (Figure 1A,B), and PBMCs from healthy controls were most responsive to indirubin in the upregulation of Tregs at the dose of 2 µmol/L (Figure 1C). The percentages of CD4+ T cells among the PBMCs cultured were unchanged after respective treatments compared with DMSO controls (Figure 1D,E). Dexamethasone was used as a positive control for it was reported to enhance Tregs in the treatment of ITP. To explore whether indirubin could enhance the suppressive function of Tregs aside from increasing the number of Tregs, we co-cultured CFSE-labelled effector T cells with CD4+CD25+ Tregs isolated from ITP PBMCs in presence of either 1 µmol/L indirubin or 1% DMSO. For each sample run, the number of peaks was counted and the division index was calculated using FlowJo software. Tregs markedly suppressed the proliferation of effector T cells in both groups. Furthermore, indirubin could significantly enhance the inhibitory function of Tregs compared with DMSO. Indirubin itself had no apparent effect on the proliferation of effector T cells, suggesting that indirubin could enhance the function of Tregs in suppression of the proliferation of effector T cells (Figure 1F,G).

3.2 Indirubin decreased fidelity of effector T cells in a dose-dependent manner

Whether in addition to the induction of Tregs expansion, indirubin could influence the function of effector T cells was unknown. In the culturing of PBMCs from ITP patients, we found the expression of CD25 in CD4+ T cells (Figure 2A,B), CD4+CD45RA+ T cells (Figure 2C) and CD4+CD45RO+ T cells (Figure 2D) were significantly reduced after treated with indirubin in a dose-dependent manner, indicating that indirubin could decrease the activation of effector T cells in ITP. However, PBMCs from healthy controls did not show obvious changes in the activation of effector T cells after indirubin treatment (Figure 2E). We further tested the apoptosis level of PBMCs after treated with indirubin at different doses. We stained PBMCs with Annexin V and propidium iodide (PI) following co-culturing with indirubin or DMSO for 72 hours. The percentage of apoptotic cells were considered as Annexin V-positive and PI-negative. Indirubin could only induce the apoptosis of PMBCs from ITP patients at higher doses of 2 and 10 µmol/L (Figure 2F,H), and the apoptosis level of PBMCs from healthy controls did not change much after indirubin treatment (Figure 2G). We then selected 1 µmol/L indirubin as the optimal dose as it could significantly induce the number and function of Tregs as well as dampen the activation of effector T cells without apparent induction of apoptosis.

3.3 Indirubin normalized decreased PD1 and PTEN expression on CD4+ T cells of ITP patients

The PD1-PDL1 pathway, a pivotal modulator of T-cell homeostasis and Tregs development, is critical for limiting the immune response and thwarting the development of autoimmunity. Not surprisingly, it has been reported that PD1 is found to be decreased on the surface of PBMCs of ITP patients. However, the expression of PD1 on CD4+ T cells in ITP patients has not been reported. We found reduced PD1 expression on CD4+ T cells and increased PD1 expression on CD4+ monocytes of ITP patients compared with healthy controls (Figure 3A,B). The mRNA expression level of PD1 on PBMCs from ITP patients was higher than that from healthy controls (0.0008 ± 0.01, n = 16 vs 0.0027 ± 0.03, n = 27, P = 0.0215, Mann–Whitney test). (E,F) The PD1 expression on CD4+ monocytes and CD4+ T cells had no significant differences between ITP patients and healthy controls. (F,G) Phosphatase and tensin homolog expression on CD4+ T cells and PTEN mRNA expression level on PBMCs were significantly suppressed in ITP patients compared to healthy controls (1.26 ± 0.65, n = 11 vs 0.92 ± 0.20, n = 20, P = 0.0393; 0.096 ± 0.050, n = 15 vs 0.066 ± 0.034, n = 19, P = 0.0429, Student’s t test). (H,J) Indirubin increased the PD1, PTEN mRNA expression on PBMCs from ITP patients (PTEN: 1.87 ± 0.62, P = 0.0269, n = 7, paired Student’s t test). The PBMCs from healthy controls did not show significant changes in the PD1, PTEN mRNA expression level after indirubin treatment. (J,K) Indirubin significantly increased PD1 expression on CD4+ T cells (4.22 ± 2.35 vs 6.13 ± 1.98, n = 6, P = 0.0391, Wilcoxon matched-pairs signed rank test) and Tregs (7.06 ± 5.31 vs 11.70 ± 9.21, n = 7, P = 0.0061, paired Student’s t test). **P < 0.05, ***P < 0.01.
mRNA expression levels, though the increasing of PD1 mRNA expression was not significant (Figure 3H,I), thus indicating that indirubin’s therapeutic action on Tregs and effector T cells might be through the induction of PD1 and PTEN expression and signalling in ITP. The PBMCs from healthy controls did not show significant changes in the PD1, PTEN mRNA expression level after indirubin

**FIGURE 4** Indirubin ameliorated thrombocytopenia in an active immune thrombocytopenia (ITP) murine model with increased splenic Tregs and programmed cell-death 1 (PD1) and PDL1 expression. (A) Immune thrombocytopenia was established in irradiated Severe combined immunodeficient mice with engraftment of 5 × 10⁵ splenocytes from CD61 KO mice immunized against wild type C57 mice platelets. Platelet counts were monitored every week for 5 wk. Treatment with indirubin (40 mg/kg) or control (coin oil) was administered on day 13. On day 21, a significantly higher platelet count was observed in the indirubin-treated group compared to control group (728.33 ± 215.26 vs 403.33 ± 111.83; \( P = 0.0015 \)). The horizontally dotted lines represent the normal platelet range. Significance among groups was determined by Student’s t test, \( n = 6 \) and 7 for indirubin and control group respectively. Spleens, thymuses and bone marrow were harvested from ITP mice at 35 d post splenocytes transfer (23 d after indirubin treatment). (B,C) indirubin-treated ITP mice had a higher percentage of splenic Tregs (6.14 ± 0.19 vs 10.92 ± 1.90, \( P = 0.005 \)) and lower percentage of thymic Tregs (9.12 ± 3.56 vs 6.39 ± 2.46, \( P = 0.129 \)) compared with the control ITP mice. (D-I) The expression of PD1 (0.77 ± 0.23 vs 1.27 ± 0.36, \( P = 0.047 \)), and PDL1 (2.99 ± 0.42 vs 3.8 ± 0.55, \( P = 0.045 \)) on CD4⁺ T cells and the expression of PDL1 on APCs (2.17 ± 0.50 vs 3.42 ± 0.32, \( P = 0.002 \)) were upregulated in the spleen, as well as PDL1 on APCs from bone marrow (1.63 ± 0.17 vs 2.22 ± 0.40, \( P = 0.027 \)), whereas no significant changes of PD1, PDL1 expression on CD4⁺ T cells from bone marrow. Differences between two groups were determined by Student’s t test, \( n = 4 \) for control group, and \( n = 5 \) for indirubin group. *\( P < 0.05 \), **\( P < 0.01 \).
treatment (Figure 3H,I), nor did the PD1 expression on CD4+ T cells (data not shown).

3.4 | Indirubin ameliorated thrombocytopenia in an active murine model

It has been reported previously that indirubin was effective therapeutically in an ITP murine model.31 However, the animal model used in the previous study could not explain the pathogenesis of ITP sufficiently. To assess whether our in vitro observations were reproducible in vivo, we adopted an active ITP murine model. This is currently the optimal model in mimicking human chronic ITP as it encompasses both antibody-mediated and cell-mediated platelets and megakaryocytes destruction.44 Following the radiation and transfer of anti-CD61 immune-sensitized splenocytes into SCID mice, platelet counts dropped to nadir on day 7. Indirubin (40 mg/kg) or control treatment (corn coil) was administered via intraperitoneal injections on day 13. On day 21, significantly higher platelet counts were observed in the indirubin-treated group compared to control group (Figure 4A). To further investigate the molecular mechanisms of therapeutic efficacy of indirubin in vivo, we quantified the percentage of CD4+CD25+Foxp3+ Tregs from the spleen and thymus as well as the expression of PD1, PDL1 in the ITP mice. Compared with the control group, indirubin treatment increased splenic Tregs 35 days after splenic transfer (23 days after indirubin treatment) and reduced the thymic Tregs (Figure 4B,C). The PD1 expression on CD4+ T cells was upregulated in the spleens of indirubin-treated group (Figure 4D). Moreover, PDL1 was increased on splenic CD4+ T cells and CD80+CD86+ APCs after indirubin therapy (Figure 4E,F).

3.5 | Indirubin regulated the homeostasis of CD4+ T cells via a PTEN/AKT/mTOR signalling pathway

The downstream signalling events of PD1 include augmenting PTEN expression which consequently leads to attenuation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway.45–48 This process modulates a plethora of cellular processes including energy metabolism and plays a pivotal role in the regulation of autoimmunity, inflammation, and cancer.48–51 Western blot analysis of cell lysates from CD4+ T cells cultured with 1 µmol/L indirubin revealed increased PTEN phosphorylation and decreased AKT and mTOR phosphorylation (Figure 5). These results suggested that indirubin could restore the homeostasis of CD4+ T cells in a PTEN/AKT/mTOR signalling pathway which is important in the maintenance of CD4+ T-cell homeostasis in ITP.

4 | DISCUSSION

* ZHAO ET AL. | 1895

* I tinctoria L. is an herb used in ancient China for the treatment of thrombocytopenia. Its effect is mild and persistent, and therefore is usually used as an assistant therapy for the treatment of ITP nowadays. Indirubin is an active ingredient of I tinctoria L., and is well known for its anti-cancer and anti-inflammatory effects.25 In addition, indirubin has also been reported to be an effective treatment in autoimmune diseases.52 ITP is a multifaceted autoimmune disease, and its complex pathogenic mechanisms still remain to be fully elucidated. One of the major contributing factors to the immuno-pathogenesis of ITP is the disturbance of the T-cell homeostasis including the peripheral deficiency of Tregs and over-activation of effector T cells.5–8,14–16 In animal experiments, indirubin was found to increase
the percentage and number of Tregs in murine models of ITP and ulcerative colitis. 27,31

In our present study, we showed that indirubin enhanced Tregs development and improved Tregs function of ITP patients in vitro. Beyond its effects on Tregs, indirubin also exerted a regulatory role on CD4+ effector T cells as dampening the activation of effector T cells. Furthermore, we found lower PD1 and PTEN expression in CD4+ T cells from ITP patients compared to healthy controls, which could be rectified after indirubin treatment. The PD1-PDL1 pathway regulates peripheral T-cell tolerance in several ways. On the one hand, this pathway impairs the initial phase of activation, expansion, differentiation, survival, and functions of self-reactive T cells. On the other hand, this pathway facilitates the development, maintenance, and function of induced Tregs.33,52-55 Signalling through the PD1-PDL1 pathway also regulates the dynamic interplay between Tregs and effector T cells.56 The combination of PD1 and PDL1 limits T-cell stimulation and promotes the differentiation and stabilization of Tregs by augmenting the expression of PTEN, a cellular phosphatase which inhibits the PI3K/AKT/mTOR pathway.45-48 The reduced expression of PD1 and PTEN on CD4+ T cells of ITP patients may contribute to the disturbance of CD4+ T-cell homeostasis in ITP. In our in vitro study, indirubin was found to increase the PD1 expression on CD4+ T cells of ITP patients and induce the phosphorylation of PTEN, with the downstream dephosphorylation of p-AKT and p-mTOR.

We established the active murine ITP model, and significant amelioration of thrombocytopenia was found 7 days after indirubin administration, implicating a therapeutic role of indirubin in ITP. It has been reported in murine models of ITP that thrombocytopenia was correlated with a significant splenic Tregs deficiency and a concomitant thymic retention of Tregs, which was reversed upon amelioration of ITP.22 Similarly, in our murine ITP model, we found successful indirubin treatment correlated with an increase of splenic Tregs percentage and a concurrent reduction in the thymic Tregs. Furthermore, in accordance with our in vitro study, our in vivo study revealed the upregulated expression of PD1 on CD4+ T cells in the spleens from ITP mice treated with indirubin. Moreover, the expression of PDL1 was also increased on the CD4+ T cells and APCs after indirubin treatment.

To the best of our knowledge, this is the first time to demonstrate that indirubin may exert its effects through the PD1-PDL1 axis which has a significant role in reinstating T-cell homeostasis and re-establishing peripheral tolerance. In our future study, we plan to use the PD1+ mice to establish the ITP murine model and further elucidate the correlation between ITP and PD1 signalling pathway, and the mechanisms of indirubin in a deeper facet. We also plan to register a randomized controlled clinical trial to investigate the therapeutic effect of indirubin on ITP patients clinically.

In summary, indirubin modulated the T-cell homeostasis by enhancing the development and function of Tregs and reducing the activation of effector T cells via a PD1/PTEN/AKT signalling pathway. This novel mechanism of indirubin underlies the potential therapeutic strategy for ITP.

ACKNOWLEDGEMENTS
We thank Junling Liu for providing C57BL/6 CD61-KO mice. We thank John W. Semple, Heyu Ni, Li Guo, Rukhsana Aslam, Edwin R. Speck and Anne Zufferey for technical assistance. We also thank Sahil Gupta for helpful suggestions. This work was supported by grants from National Natural Science Foundation of China (NSFC, No. 81770114, No. 81470284, No. 81770133, No. 81570103, No. 81500094, No. 81600091, No. 81700113), Leading research group of scientific innovation, Major Research Plan of National Natural Science Foundation of China (No. 91442204), Major Research Plan of National Science Foundation of Shandong Province (ZR2016QZ008), Natural Science Foundation of Shandong Province (ZR2017PH022, ZR2017PH041), State Key Clinical Specialty of China for Haematological Diseases and Taishan Scholar of Shandong Province. Y.-J.Z. and M.H. designed and performed research, analyzed data, and wrote the paper; P.-P.H., L.L., X.-J.W., Y.-Q.S., T.-S.Y., H.-Y.W., P.-C.X. performed research and analyzed data; X.-G.L., L.Z.L., T.S., J.-H.Q., H.Z., L.W., and J.P. evaluated the data and corrected the paper; S.-Q.X. and M.H. designed and reviewed the work; and all authors read and edited the manuscript.

CONFLICT OF INTEREST
The authors confirm that there are no conflicts of interest.

ORCID
Yajing Zhao https://orcid.org/0000-0002-6288-8688
Liang Wang https://orcid.org/0000-0003-0574-3543

REFERENCES
1. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010;115:1247-1253.
2. Semple JW, Provan D. The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Curr Opin Hematol. 2012;19:357-362.
3. McKenzie CG, Guo L, Freedman J, Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol. 2013;163:10-23.
4. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6:16.
5. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood. 1991;78:2619-2625.
6. Ware RE, Howard TA. Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura. Blood. 1993;82:2137-2142.
7. Cines DB, Cuker A, Semple JW. Pathogenesis of immune thrombocytopenia. Presse Med. 2014;43:e49-59.
8. Li F, Ji L, Wang W, et al. Insufficient secretion of IL-10 by Tregs compromised its control on over-activated CD4+ T effector cells in
newly diagnosed adult immune thrombocytopenia patients. *Immunol Res.* 2015;61:269-280.

9. Cao J, Chen C, Li L, et al. Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia. *J Clin Immunol.* 2012;32:523-529.

10. Guo XH, Zhao F, Shi W, et al. [Detection and clinical significance of Th1/Th2 cytokines in patients with idiopathic thrombocytopenic purpura]. *Xiu Bao Yu Fen Zi Mian Yi Xue Za Zhi.* 2012;28:1185-1187.

11. Hu Y, Li H, Zhang L, et al. Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. *Hum Immunol.* 2012;73:629-635.

12. Yu S, Liu C, Li L, et al. Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia. *Lab Invest.* 2015;95:157-167.

13. Qiao J, Li X, Wu Y, et al. An increased expression profile of Th9/IL-9 correlated with Th17/IL-17 in patients with immune thrombocytopenia. *Platelets.* 2017;28:287-294.

14. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. *Blood.* 2008;112:1147-1150.

15. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenia. *Blood.* 2008;112:1325-1328.

16. Zhang XL, Peng J, Sun JZ, et al. De novo induction of platelet-specific CD4+CD25+ regulatory T cells from CD4+CD25- cells in patients with idiopathic thrombocytopenic purpura. *Blood.* 2009;113:2568-2577.

17. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. *Blood.* 2010;116:4639-4645.

18. Sakaguchi S, Miyara M, Costantino CM, Hafer DA. FOXP3+ regulatory T cells in the human immune system. *Nat Rev Immunol.* 2010;10:490-500.

19. Nishimoto T, Kuswana M, CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. *Semin Hematol.* 2013;50(Suppl 1):S43-549.

20. Hull CM, Peakman M, Tree T. Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it? *Diabetologia.* 2017;60:1839–1850.

21. Qiao YC, Pan YH, Ling W, et al. The Yin and Yang of regulatory T cell and therapy progress in autoimmune disease. *Autoimmun Rev.* 2017;16:1058-1070.

22. Aslam R, Hu Y, Gebremeskel S, et al. Thymic retention of CD4+CD25+Foxp3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. *Blood.* 2012;120:2127-2132.

23. Li Z, Mou W, Lu G, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. *Int J Hematol.* 2011;93:91-98.

24. Li J, Wang Z, Hu S, Zhao X, Cao L. Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. *Immunol Lett.* 2013;154:42-48.

25. Gaboriaud-Kolar N, Youvgiannopoulou K, Skaltsounis AL. Indirubin derivatives: a patent review (2010-present). *Expert Opin Ther Pat.* 2015;25:583-593.

26. Memari B, Bouttier M, Dimitrov V, et al. Engagement of the aryl hydrocarbon receptor in mycobacterium tuberculosis-infected macrophages has pleiotropic effects on innate immune signaling. *J Immunol.* 2015;195:4479-4491.

27. Gao W, Guo Y, Wang C, et al. Indirubin ameliorates dextran sulfate sodium-induced ulcerative colitis in mice through the inhibition of inflammation and the induction of Foxp3-expressing regulatory T cells. *Acta Histochem.* 2016;118:606-614.

28. Kwok HH, Poon PY, Fok SP, et al. Anti-inflammatory effects of indirubin derivatives on influenza A virus-infected human pulmonary microvascular endothelial cells. *Sci Rep.* 2016;6:18941.

29. Lai JL, Liu YH, Peng YC, et al. Indirubin treatment of lipopolysaccharide-induced mastitis in a mouse model and activity in mouse mammary epithelial cells. *Mediators Inflamm.* 2017;2017:3082805.

30. Medina-Moreno S, Dowling TC, Zapata JC, et al. Targeting of CD9 with indirubin 3’-monoxide safely and durably reduces HIV viremia in chronically infected humanized mice. *PLoS ONE.* 2017;12:e0183425.

31. Zhang A, Ning B, Sun N, Wei J, Ju X. Indirubin increases CD4+CD25+Foxp3+ regulatory T cells to prevent immune thrombocytopenia in mice. *PLoS ONE.* 2015;10:e0142634.

32. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev.* 2010;236:219-242.

33. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. *J Exp Med.* 2003;198:63-69.

34. Wang J, Yoshida T, Nakaki H, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type 1 diabetes. *Proc Natl Acad Sci U S A.* 2005;102(13):11823–11828.

35. Raptopoulou AP, Bertsias G, Makrygiannakis D, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. *Arthritis Rheum.* 2010;62:1870-1880.

36. Pittet CL, Newcombe J, Prat A, Arbour N. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. *J Neuroinflammation.* 2011;8:155.

37. Wong M, La Cava A, Hahn BH. Blockade of programmed death-1 in young (New Zealand Black n New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. *J Immunol.* 2013;190:5402-5410.

38. Li S, Liao W, Chen M, et al. Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis. *Inflammation.* 2014;37:116-121.

39. Zhong J, Chen S, Xu L, et al. Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP. *Hematology.* 2016;21:552-557.

40. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood.* 2011;117:4190-4207.

41. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med.* 2009;206:3015-3029.

42. Giancchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. *Autoimmun Rev.* 2013;12:1091-1100.

43. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. *Clin Immunol.* 2014;153:145-152.

44. Hou Y, Feng Q, Xu M, et al. High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia. *Blood.* 2016;127:1587-1597.

45. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. *J Exp Med.* 2008;205:565-574.

46. Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. *Proc Natl Acad Sci U S A.* 2008;105:7797-7802.

47. Huhyn A, DuPage M, Priyadharshini B, et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. *Nat Immunol.* 2015;16:188-196.
48. Sharma MD, Shinde R, McGaha TL, et al. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci Adv. 2015;1:e1500845.
49. Koga T, Hedrich CM, Mizui M, et al. CaMK4-dependent activation of AKT/mTOR and CREM-alpha underlies autoimmunity-associated Th17 imbalance. J Clin Investig. 2014;124:2234-2245.
50. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7-24.
51. Bai D, Zhao Y, Zhu Q, et al. LZ205, a newly synthesized flavonoid compound, exerts anti-inflammatory effect by inhibiting M1 macrophage polarization through regulating PI3K/AKT/mTOR signalling pathway. Exp Cell Res. 2018;364:84-94.
52. Magiatis P, Polychronopoulos P, Skaltsounis AL, et al. Indirubins deplete striatal monoamines in the intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis. Neurotoxicol Teratol. 2010;32:212-219.
53. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203:883-895.
54. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114-125.
55. Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34:556-563.
56. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp. 2003;252:67-88; discussion 91, 106-14.

How to cite this article: Zhao Y, Han P, Liu L, et al. Indirubin modulates CD4+ T-cell homeostasis via PD1/PTEN/AKT signalling pathway in immune thrombocytopenia. J Cell Mol Med. 2019;23:1885-1898. https://doi.org/10.1111/jcmm.14089